Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 13;2(3):227–237. doi: 10.1007/s40801-015-0034-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2015

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 2 — a Percentage of all patients treated with immunosuppressive agents who were tested for HBV-DNA. For all patients already or newly receiving an immunosuppressive agent, we estimated the percentage of patients tested for HBV-DNA. Mean % [95 % CI], n number of patients tested for HBV-DNA/investigated patients in each period. b Percentage of patients in each disease type who were tested for HBV-DNA. For patients already or newly receiving an immunosuppressive agent, we estimated the percentage of patients tested for HBV-DNA in each disease type. Mean % [95 % CI], n number of patients tested for HBV-DNA/investigated patients in each period. c Percentage of patients in each drug type who were tested for HBV-DNA. For patients already or newly receiving an immunosuppressive agent, we estimated the percentage of patients tested for HBV-DNA in each drug type. Mean % [95 % CI], n number of patients tested for HBV-DNA/investigated patients in each period

Fig. 2 — a Percentage of all patients treated with immunosuppressive agents who were tested for HBV-DNA. For all patients already or newly receiving an immunosuppressive agent, we estimated the percentage of patients tested for HBV-DNA. Mean % [95 % CI], n number of patients tested for HBV-DNA/investigated patients in each period. b Percentage of patients in each disease type who were tested for HBV-DNA. For patients already or newly receiving an immunosuppressive agent, we estimated the percentage of patients tested for HBV-DNA in each disease type. Mean % [95 % CI], n number of patients tested for HBV-DNA/investigated patients in each period. c Percentage of patients in each drug type who were tested for HBV-DNA. For patients already or newly receiving an immunosuppressive agent, we estimated the percentage of patients tested for HBV-DNA in each drug type. Mean % [95 % CI], n number of patients tested for HBV-DNA/investigated patients in each period